365 related articles for article (PubMed ID: 24925090)
1. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
2. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
3. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Rocha JF; Sicard É; Fauchoux N; Falcão A; Santos A; Loureiro AI; Pinto R; Bonifácio MJ; Nunes T; Almeida L; Soares-da-Silva P
Br J Clin Pharmacol; 2017 Mar; 83(3):540-553. PubMed ID: 27763682
[TBL] [Abstract][Full Text] [Related]
4. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
5. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
6. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
8. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
[TBL] [Abstract][Full Text] [Related]
10. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
[TBL] [Abstract][Full Text] [Related]
11. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
Kuoppamäki M; Korpela K; Marttila R; Kaasinen V; Hartikainen P; Lyytinen J; Kaakkola S; Hänninen J; Löyttyniemi E; Kailajärvi M; Ruokoniemi P; Ellmén J
Eur J Clin Pharmacol; 2009 May; 65(5):443-55. PubMed ID: 19229530
[TBL] [Abstract][Full Text] [Related]
13. Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
LeWitt P; Liang GS; Olanow CW; Kieburtz KD; Jimenez R; Olson K; Klepitskaya O; Loewen G
Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):43-50. PubMed ID: 36688497
[TBL] [Abstract][Full Text] [Related]
14. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.
Almeida L; Rocha JF; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
Clin Pharmacokinet; 2013 Feb; 52(2):139-51. PubMed ID: 23248072
[TBL] [Abstract][Full Text] [Related]
16. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
17. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
19. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]